|

Alzheimer's Disease Clinical Trials in Arizona

34 recruiting studies across 3 cities

Browse by City

Mesa
32 trials
Phoenix
32 trials
Tucson
4 trials

All Trials in Arizona

Phase
Trial Phase Dist.
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Phase 3<1 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Phase 3<1 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Phase 3<1 mi
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's DiseasePhase 2<1 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseasePhase 2<1 mi
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisPhase 2<1 mi
Arizona Alzheimer's Disease Research Center (ADRC)—<1 mi
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)Phase 1/2<1 mi
PROMIS and Mobility Evaluation in Sarcoma Patients—<1 mi
Time Restricted Eating in Alzheimer's DiseaseN/A<1 mi
Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies—<1 mi
A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness ResponsesN/A<1 mi
A Study of AMDX-2011P in Participants With Alzheimer's DiseasePhase 2<1 mi
Early-Stage Partner in Care Living Alone PlusN/A<1 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Phase 3<1 mi
Goal Setting to Promote Physical Activity Adherence in Midlife AdultsN/A<1 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 3<1 mi
[18F]PI-2620 Phase 3 Histopathological StudyPhase 3<1 mi
Repurposing Siponimod for Alzheimer's DiseasePhase 2<1 mi
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's DiseasePhase 2<1 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease StudiesPhase 3<1 mi
Trial-Ready Cohort-Down Syndrome (TRC-DS)—<1 mi
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).Phase 3<1 mi
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults StudyN/A3 mi
Remote tDCS and Chair Yoga for Chronic Knee Pain in Alzheimer's PatientsN/A3 mi
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)Phase 35 mi
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)Phase 28 mi
ACP-204 in Adults With Alzheimer's Disease PsychosisPhase 2/38 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Phase 38 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)Phase 38 mi
A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease—8 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Phase 38 mi
Longitudinal Early-onset Alzheimer's Disease Study Protocol—15 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseasePhase 315 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.